Andrew has experience in venture capital, company building, technology development, and neurosurgery. He has served as founder, investor, director, and chairman of many successful companies.
Previously, he was a partner at Flare Capital Partners (formerly known as Foundation Medical Partners) and a principal at Canaan Partners. He was a founder and invented the core technology of Northstar Neuroscience, which went public and was subsequently acquired by St. Jude Medical. He also served as chairman of IntElect Medical, which was acquired by Boston Scientific. Andrew's investments prior to JAZZ include BridgePoint Medical (acquired by Boston Scientific), Explorys (acquired by IBM), Functional Neuromodulation, and Visiogen (acquired by Abbott).
Prior to venture capital, Andrew was a board-certified neurosurgeon and served as clinical assistant professor of neurosurgery at Yale School of Medicine and New York University School of Medicine. During more than a decade in the healthcare profession, he published more than 50 medical articles and was co-editor of a book about cerebrovascular surgery. His scientific work has been presented at many international conferences and he holds numerous patents for his inventions. He has served on innovation advisory boards at Yale University, Cleveland Clinic, and Cornell University. Andrew earned his MD from Weill Cornell Medicine and his MBA from the University of Pittsburgh after studying neuroscience at Cornell (AB) and Oxford University.
Andrew serves on the boards of several technology, health, consumer, and enterprise companies in the JAZZ portfolio, including AllStripes, Blue Note Therapeutics, Cadence Neuroscience, Embodied, Magnus Medical, Mahana Therapeutics, Thrive Global, Woebot, and Yumi.
